SYNAIRGEN PLC LS-,01

Synairgen shareholders at a general meeting approved a special resolution for voluntary liquidation; 965,052,834 votes were cast in favour and 510,853 against. Mark Smith and Jonathan Bass of Menzies LLP were appointed joint liquidators of Synairgen and its subsidiary Synairgen Research. The liquidators are granted the powers under the Insolvency Act 1986 to realise and distribute the company’s assets and will be remunerated on a time-cost basis. Accounting records will be kept by the company secretary for twelve months after dissolution; financial and trading records will be retained for at least six years. » Więcej na de.investing.com

Synairgen has convened a general meeting for 8 September 2026 at which shareholders will vote on initiating a Members’ Voluntary Liquidation. The board has stated that both the company and its subsidiary Synairgen Research Limited remain solvent; the sole asset is the inhaled interferon‑beta treatment SNG001. A circular with background information, the proposed resolution and voting instructions will be sent to shareholders by post and email; the announcement follows a prior notice on 31 July 2026 regarding an orderly wind‑down. » Więcej na de.investing.com

Synairgen announces completion of winding-down activities, identifies SNG001 as its sole asset, discontinues non-clinical R&D, closes sites and settles personnel and financial matters. A liquidation circular with a proposed resolution and notice of general meeting is due to be sent by the end of August 2026; the general meeting is planned for September 2026. After shareholder approval the voluntary liquidation will be initiated, a first interim payment is expected in October 2026 and a final distribution in H1 2027; the company anticipates total distributions of more than £5 million, subject to completion costs and advisory fees. » Więcej na de.investing.com